Oramed Pharmaceuticals annual net debt
2018
2019
2020
2022
2023
2024
2025
Oramed Pharmaceuticals Net Debt Growth & History (ORMP)
Oramed Pharmaceuticals's net debt was −$45.1M for fiscal 2025.
View full Oramed Pharmaceuticals company overviewOramed Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$45.1M | $8.9M | — |
| 2024 | 2024-12-31 | −$54.0M | −$96.6M | — |
| 2023 | 2023-12-31 | $42.6M | $82.1M | — |
| 2022 | 2022-12-31 | −$39.5M | — | — |
| 2020 | 2020-08-31 | −$19.3M | −$28.3M | — |
| 2019 | 2019-08-31 | $9.0M | $191,000 | +2.16% |
| 2018 | 2018-08-31 | $8.8M | — | — |
Oramed Pharmaceuticals quarterly net debt
Q4.18
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q3.22
Q3.22
Q4.22
Q1.23
Q2.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$14.5M | $373,000 | — |
| Q1 2026 | 2026-03-31 | −$12.4M | $61.8M | — |
| Q4 2025 | 2025-12-31 | −$45.1M | $8.9M | — |
| Q3 2025 | 2025-09-30 | −$51.3M | −$9.6M | — |
| Q2 2025 | 2025-06-30 | −$14.9M | $69.4M | — |
| Q1 2025 | 2025-03-31 | −$74.2M | −$88.2M | — |
| Q4 2024 | 2024-12-31 | −$54.0M | −$96.6M | — |
| Q3 2024 | 2024-09-30 | −$41.7M | — | — |
| Q2 2024 | 2024-06-30 | −$84.3M | −$78.2M | — |
| Q1 2024 | 2024-03-31 | $14.0M | $37.3M | — |
| Q4 2023 | 2023-12-31 | $42.6M | $82.1M | — |
| Q2 2023 | 2023-06-30 | −$6.0M | $15.6M | — |
| Q1 2023 | 2023-03-31 | −$23.3M | — | — |
| Q4 2022 | 2022-12-31 | −$39.5M | — | — |
| Q3 2022 · Sep 30 | 2022-09-30 | −$27.1M | — | — |
| Q3 2022 · Jun 30 | 2022-06-30 | −$21.6M | — | — |
| Q1 2022 · Nov 30 | 2021-11-30 | −$19.7M | −$5.4M | — |
| Q3 2021 | 2021-05-31 | −$56.9M | −$47.6M | — |
| Q2 2021 | 2021-02-28 | −$33.2M | −$27.4M | — |
| Q1 2021 | 2020-11-30 | −$14.3M | −$11.2M | — |
| Q4 2020 | 2020-08-31 | −$19.3M | −$28.3M | — |
| Q3 2020 | 2020-05-31 | −$9.2M | — | — |
| Q2 2020 | 2020-02-29 | −$5.8M | — | — |
| Q1 2020 | 2019-11-30 | −$3.1M | — | — |
| Q4 2019 | 2019-08-31 | $9.0M | $191,000 | +2.16% |
| Q4 2018 | 2018-08-31 | $8.8M | — | — |
Oramed Pharmaceuticals net debt trends
Between the periods ended 2018-08-31 and 2025-12-31, Oramed Pharmaceuticals's net debt decreased from $8.8M to −$45.1M, a change of −$54.0M. The latest reported quarter, Q2 2026, shows −$14.5M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oramed Pharmaceuticals source filings ↗